Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
about
A structured review of health utility measures and elicitation in advanced/metastatic breast cancerLapatinib for the treatment of breast cancer in the People's Republic of China.Role of lapatinib in the first-line treatment of patients with metastatic breast cancer.Is progression-free survival associated with a better health-related quality of life in patients with lung cancer? Evidence from two randomised trials with afatinib.Quality of life in hormone receptor-positive HER-2+ metastatic breast cancer patients during treatment with letrozole alone or in combination with lapatinibRole of lapatinib alone or in combination in the treatment of HER2-positive breast cancerLapatinib in patients with metastatic breast cancer following initial treatment with trastuzumab: an economic analysis from the Brazilian public health care perspective.Long-term health status as measured by EQ-5D among patients with metastatic breast cancer: comparison of first-line oral S-1 and taxane therapies in the randomized phase III SELECT BC trialLapatinib plus letrozole for postmenopausal patients with advanced HER2(+)/HR(+) breast cancer.Lapatinib for breast cancer: a review of the current literature.Quality of life assessments in advanced breast cancer: should there be more consistency?Systemic treatment of HER2-positive metastatic breast cancer: a systematic review.The use of patient-reported outcomes in advanced breast cancer clinical trials: a review of the published literature.Health state utility values in locally advanced and metastatic breast cancer by treatment line: a systematic review.Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer.Measurement of HER2 in saliva of women in risk of breast cancer.Health-related quality of life of patients with advanced breast cancer treated with everolimus plus exemestane versus placebo plus exemestane in the phase 3, randomized, controlled, BOLERO-2 trial.Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.Quality of Life in Patients with Advanced Cancer Using the Functional Assessment of Cancer Therapy-General Assessment Tool: A Literature Review.Impact of palbociclib plus letrozole on patient-reported health-related quality of life: results from the PALOMA-2 trial.Value assessment in oncology drugs: funding of drugs for metastatic breast cancer in Canada.
P2860
Q28067255-7908A9B4-BE92-4CA2-86B3-F6D572425E8AQ34016491-2DC8F93A-26A2-45F9-BD9E-A8D424C4EC66Q34417920-071469D7-2DF5-47F4-8AD8-8685C219A6B9Q34439059-75FBE12D-06EA-4F51-AD2E-CA7E03BC6E02Q35584250-A3475874-C65A-420D-9A97-B984FC47F320Q37355762-3EFAB977-B244-4A98-AB52-65F8C6237951Q37355937-CA522C38-7E06-415B-9236-267B35254965Q37620096-EEDE01F1-5B2C-46E0-917A-3F742C37757EQ37628693-3C56D07C-46AC-4808-AD9F-18EEC74E7482Q37810946-0B454890-E588-4087-A1A6-9B2FFAB3972EQ38016575-1E8FAA67-91F4-44AB-BDB7-358FA4D139A0Q38209463-27AD7EEF-223D-4D26-A406-5B1BC09C4BD9Q38872926-ECA3CBD5-2DC6-4B46-9487-B1D94D576371Q38940841-1F9AD1E8-A705-4407-8284-77F29234D2E6Q44153213-223FAC29-56D3-4DB2-A154-0C749E7B4B41Q44386208-500F6268-2A6F-4CDF-A8A5-00E4F1CEAB6DQ45754894-BFCAB8BE-47F9-4185-92B1-1AE88E5274A2Q46434054-30F1AD29-39B3-452D-977E-9080D3901286Q47110902-6077AFA5-14A6-4500-BDB3-A849336A7F34Q52707821-390628D7-CBE9-42E6-9B2A-0DE5A9E7790EQ55365709-AFF7D533-63EB-4081-A95D-89C7BA52F32A
P2860
Lapatinib plus capecitabine versus capecitabine alone for HER2+ (ErbB2+) metastatic breast cancer: quality-of-life assessment.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Lapatinib plus capecitabine ve ...... r: quality-of-life assessment.
@en
Lapatinib plus capecitabine versus capecitabine alone for HER2+
@nl
type
label
Lapatinib plus capecitabine ve ...... r: quality-of-life assessment.
@en
Lapatinib plus capecitabine versus capecitabine alone for HER2+
@nl
prefLabel
Lapatinib plus capecitabine ve ...... r: quality-of-life assessment.
@en
Lapatinib plus capecitabine versus capecitabine alone for HER2+
@nl
P2093
P1476
Lapatinib plus capecitabine ve ...... r: quality-of-life assessment.
@en
P2093
Anthony Segreti
Charles E Geyer
David Cameron
David Cella
Mayur M Amonkar
Mel Walker
Steven Stein
Xiaolei Zhou
P2888
P304
P356
10.1007/S10549-009-0310-8
P407
P577
2009-01-20T00:00:00Z